Fig. 1.
Tumor-free survival curves of SCID mice bearing subcutaneous RPMI 8226 tumors. SCID mice were treated with 20 μg/dose of control IgG (○, day 1 to 4), anti-HM1.24 F(ab′)2 (□, day 1 to 4), anti-HM1.24 IgG (•, day 1), or anti-HM1.24 IgG (▪, day 1 to 4) after tumor inoculation. There were five animals per group.